BOSTON, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq:ZIOP) today announced that Chief Executive Officer Laurence Cooper, M.D., Ph.D, is scheduled to present and participate in a panel discussion on Feb. 26 at the CAR-TCR Summit Europe in London.
Panel Discussion: “Explore the Need to Reduce the Cost of Manufacturing in Order to Ensure Feasible Reimbursements”
When: Tuesday, Feb. 26 at 4:15 p.m. GMT
Presentation: “Non-viral Gene Transfer to Commercialize T-cell Therapies”
When: Tuesday, Feb. 26 at 5:15 p.m. GMT
The summit is being held Feb. 25-27 at the Novotel London West, 1 Shortlands, Hammersmith, London. For more information, visit: http://cartcr-europe.com/
About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-end cost-effective solutions using its non-viral Sleeping Beauty platform for TCR and CAR-T cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors, and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company’s very rapid T-cell manufacturing process. The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform or Ad-RTS-hIL-12 plus veledimex as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Vice President, Corporate Communications and Investor Relations
Vice President, Portfolio Strategy
Source: ZIOPHARM Oncology Inc